Exh. 99.1


                    SEVENTH AMENDMENT TO CONSULTING AGREEMENT


         This SEVENTH AMENDMENT TO CONSULTING AGREEMENT (the "Amendment") is
effective as of the 1st day of January 2005 (the "Effective Date"), by and
between JOHN M. PIETRUSKI, an individual residing at 27 Paddock Lane, Colts
Neck, New Jersey 07722 ("Consultant"), and ENCYSIVE PHARMACEUTICALS INC., a
Delaware corporation located at 6700 West Loop South, Suite 400, Bellaire, Texas
77401 (the "Corporation").

         WHEREAS, the Corporation and Consultant have entered into that certain
Consulting Agreement, dated January 1, 1992 (the "Agreement"), as set forth in
Exhibit "A" attached hereto and incorporated herein by reference; and

         WHEREAS, pursuant to the Agreement, the Corporation has retained
Consultant to provide consulting services to the Corporation with respect to
corporate governance, business development and other such matters; and

         WHEREAS, the Corporation and Consultant desire to amend the Agreement
as herein set forth.

         NOW, THEREFORE, for and in consideration of the foregoing and of the
mutual covenants contained herein, the parties hereto agree as follows:

         1. Definitions. If not otherwise defined herein, all capitalized terms
used herein shall have their respective meaning assigned to them in the
Agreement.

         2. Amendment to Section 2. Effective as of the date hereof, Section 2
of the Agreement is hereby amended by deleting paragraph (a) in its entirety and
substituting the following in lieu thereof:

                  "(a) Consultant's retention under this agreement shall
         commence on the date hereof (the "Commencement Date") and shall end on
         the earliest of: (i) the death or disability (as defined herein) of
         Consultant; (ii) the termination of Consultant's retention by the
         Corporation for cause (as defined herein); or (iii) two years after the
         Effective Date. After the expiration of such two-year period, this
         Agreement may be renewed for additional periods on all the remaining
         terms and conditions set forth herein upon mutual agreement of
         Consultant and the Corporation."

         3. Amendment to Section 3. Effective as of January 1, 2005, Section 3
of this Agreement is hereby amended by amending the fee rate to be $40,000 per
annum.

         4. The terms and provisions set forth in this Amendment shall modify
and supersede all inconsistent terms and provisions set forth in the Agreement
and except as expressly modified and superseded by this Amendment, the terms and
provisions of the Agreement are ratified and confirmed and shall continue in
full force and effect. Corporation and Consultant agree that the Agreement as
amended shall continue to be legal, valid, binding and enforceable in accordance
with its terms.





         5. Except as expressly modified or amended hereby, the terms and
provisions of the Agreement shall remain in force and effect in accordance with
the terms hereof; provided, however, that from and after the date hereof any
reference to the Agreement shall be deemed and construed as meaning the
Agreement as amended and modified hereby.

         IN WITNESS WHEREOF, the parties have executed this Amendment as of the
day and year first written above.


                          CONSULTANT:

                          /s/ John M. Pietruski                  January 5, 2005
                          ------------------------------------------------------
                          John M. Pietruski                        Date



                          CORPORATION:

                          ENCYSIVE PHARMACEUTICALS INC.

                          /s/ Bruce D. Given, M.D.               January 4, 2005
                          ------------------------------------------------------
                          Bruce D. Given, M.D.                     Date
                          President and Chief Executive Officer